AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01410942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Exercise Intervention Program
Description: Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
Study NCT01935856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: Oral administration
Study NCT01410942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
Study NCT01410942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
Study NCT03224416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Administration
Description: In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
Study NCT04404088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT04404088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT04404088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02895854 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated RT 5 x 7,25 Gy
Study NCT02895854 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LDR-brachytherapy with I125 seeds
Study NCT01703988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Single IT injection for each dose
Study NCT02446262 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Instructions
Description: In sub-study 1, half the participants are instructed about outcomes, half learn through experience.
Study NCT03224416 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Alcohol Administration
Description: In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims.
Study NCT03224416 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Alcohol Administration
Description: In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
Study NCT01075646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Laparotomy of colorectal surgery: 10 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 5ml/h.~Laparoscopy of colorectal surgery: 5 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 2 ml/h.~Hepatic surgery: 10 ml de ropivacaine 0,45% + infusion with elastomeric pump with ropivacaine 0,23 at a 5ml/h.
Study NCT01075646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Laparotomy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h.~Laparoscopy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 2 ml/h.~Hepatic surgery: 10 ml de saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h
Study NCT02807506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Service Robot
Description: The goal is to build a low-cost mobile service robot with an arm that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
Study NCT02446262 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention
Description: In sub-study 4, participants learn about outcomes and we manipulate attention toward or away from the pain.
Study NCT02446262 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Thermal Pain
Description: In sub-studies 2 and 3, participants are exposed to thermal stimuli and/or tastants (sugar water, salt water, neutral rinse) and we are measuring how learning varies based on the type of outcome.
Study NCT02446262 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Placebo instructions
Description: In sub-study 5, we test whether placebo effects and expectancy cues modulate pain through similar mechanisms.
Study NCT03496168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: mavacamten capsules
Study NCT03287453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: View an inflatable colon interactive exhibit, PowerPoint presentation, flip books, and flipcharts
Study NCT03287453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT01845974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermoCool® SF NAV Catheter
Description: The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
Study NCT01845974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThermoCool® catheter
Description: The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
Study NCT02807506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot.
Study NCT03028337 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spine Radiosurgery
Description: Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction).
Study NCT02735512 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and urine samples
Study NCT03028337 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Spine Radiosurgery
Description: Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction).
Study NCT03028337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up.
Study NCT03028337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up.
Study NCT02285114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: F/TAF tablets administered orally once daily
Study NCT02735512 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Samples undergo MDSC clinical assay
Study NCT02980341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan
Description: U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
Study NCT01996410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Study NCT02015416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDC-G305
Description: NY-ESO-1 recombinant protein together with GLA-SE
Study NCT01788189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT03146689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical NSAID
Description: Applied four times daily
Study NCT03146689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Capsaicin
Description: Applied four times daily
Study NCT01953601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verubecestat 12 mg (Parts 1 and 2)
Description: Verubecestat 12 mg oral tablet, given once daily.
Study NCT01953601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verubecestat 40 mg (Parts 1 and 2)
Description: Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.
Study NCT01953601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Verubecestat 40 mg (Parts 1 and 2)
Description: Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.
Study NCT01953601 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1)
Description: Placebo matching verubecestat, given once daily as an oral tablet.
Study NCT03891043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: A 100 micrograms of Selenium was given to be taken twice a day.
Study NCT03891043 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill of 100 micrograms of starch was given to be taken twice a day.
Study NCT00239746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 200mg taken orally daily for 6-12 weeks
Study NCT00239746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg matched placebo taken orally daily for 6-12 weeks
Study NCT00692848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin dosage PCT-Q test (Brahms, Germany)
Description: Procalcitonin result available to the attending physician
Study NCT02250482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optivate® (Human Coagulation Factor VIII)
Study NCT01493284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation
Description: Placement of the SJM Portico aortic valve with a transfemoral delivery system
Study NCT03453034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3233
Description: QD or BID in different stage of this research
Study NCT00539162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires completed at baseline and during each follow up visit.
Study NCT01872598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Study NCT01872598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01872598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
Study NCT01872598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
Study NCT01159366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: early timing
Study NCT04169048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group training for mothers with Borderline Personality Disorder
Description: The group programme is designed to teach mothers with BPD parenting skills and to reduce dysfunctional parenting attitudes and strategies. The components are: childrens basics needs, mindfulness, stress and stress reduction, dealing with conflicts, dealing with emotions, dysfunctional attitudes, physical contact, parenting rules, self care.
Study NCT02329067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walnuts
Description: consumption of 43 g walnuts per day
Study NCT02285114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3rd ARV agent
Description: A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).
Study NCT02285114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boosted PIs
Description: Boosted PIs of the participant's pre-existing regimen may include one of the following: ATV, LPV, or DRV.
Study NCT03982459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision support tool
Description: Internet-Based, interactive decision support tool
Study NCT00633633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Monthly visits with the cardiology team and a booklet about coping with heart failure.
Study NCT00633633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Monthly visits with the cardiology team and a booklet about coping with heart failure.
Study NCT00633633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Exercise training 3 times a week.
Study NCT00633633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Food log, booklet, and a cookbook to help decrease the salt content in your diet.
Study NCT03599661 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Participants will review a computer prototype of Fertilit-e alpha. Using an interview guide, participants will be asked about issues of content, functionality, and ease of use (i.e., comprehensibility and usability). Interviews will be completed within 45-60 minutes.
Study NCT03599661 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: All participants will complete an interviewer administered screener for health literacy and self-report items for technology use, eHealth literacy, and need for cognition.
Study NCT04273945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan 10 mg
Description: Participants will receive macitentan 10 mg film-coated tablets orally.
Study NCT04273945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Description: Participants will receive macitentan 10 mg film-coated tablets orally.
Study NCT04273945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan 37.5 mg
Description: Participants will receive macitentan 37.5 mg film-coated tablets orally.
Study NCT04273945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 37.5 mg
Description: Participants will receive macitentan 37.5 mg film-coated tablets orally.
Study NCT04273945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan 75 mg
Description: Participants will receive macitentan 75 mg film-coated tablets orally.
Study NCT04273945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 75 mg
Description: Participants will receive macitentan 75 mg film-coated tablets orally.
Study NCT04273945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo film-coated tablets orally.
Study NCT04273945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo film-coated tablets orally.
Study NCT03866668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
Study NCT01659892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 5 mg Chewable Tablet
Study NCT01659892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Description: 5 mg Chewable Tablet
Study NCT03929562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: One 10-minute brief advice session
Study NCT03929562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Two 45-minute health coaching sessions will use a non-confrontation motivational interviewing (MI) style. Intervention delivery will include expressing concern about unhealthy drinking, providing feedback linking alcohol use and health (related to surgery and general health), advising the patient regarding abstinence or alcohol use reduction, and working with the patient to set a drinking goal if he/she is ready to change. We will also include a personalized feedback component to address the links between pre-operative alcohol use and postoperative morbidity/mortality.
Study NCT04077255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-EGFR antibody in combination with weekly paclitaxel
Description: Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy
Study NCT02556151 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive lumbosacral magnetic stimulation (rTLSMS)
Description: Patients randomized to Six sessions of weekly therapy with either 1 HZ or 5 Hz or 15 Hz magnetic stimulations of the lumbar and sacral regions.
Study NCT04251871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules
Description: Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days.
Study NCT04251871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)
Description: Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
Study NCT01417611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: i-scan CE, SE, TE mode
Description: I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.
Study NCT03219008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.
Study NCT03219008 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: fluoxetine + cognitive-behavioral treatment（CBT）
Description: the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.
Study NCT03219008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine + Amfebutamone
Description: Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.
Study NCT03219008 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: physical treatment+fluoxetine+amfebutamone
Description: the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.